NCT05850546View on ClinicalTrials.gov

Rituximab in the First Episode of Paediatric Nephrotic Syndrome

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

July 30, 2026

Study Completion Date

December 28, 2026

Conditions
Steroid-Sensitive Nephrotic Syndrome
Interventions
DRUG

Rituximab

Rituximab 375 mg/m2 added to guideline-recommended corticosteroid therapy

DRUG

Corticosteroid

guideline-recommended corticosteroid therapy

Trial Locations (3)

Unknown

Children's hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

Shanghai's Children's Medical Center, Shanghai

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
collaborator

Shanghai Shen Kang Hospital Development Center

OTHER

collaborator

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

collaborator

Shanghai Children's Medical Center

OTHER

collaborator

Shanghai Children's Hospital

OTHER

lead

Children's Hospital of Fudan University

OTHER